BioVie (BIVI) Competitors $6.03 +0.02 (+0.33%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.10 +0.06 (+1.08%) As of 08/1/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BIVI vs. APLT, RPTX, CRVO, ASRT, STRO, HOWL, SCLX, IKNA, BRNS, and MNOVShould you be buying BioVie stock or one of its competitors? The main competitors of BioVie include Applied Therapeutics (APLT), Repare Therapeutics (RPTX), CervoMed (CRVO), Assertio (ASRT), Sutro Biopharma (STRO), Werewolf Therapeutics (HOWL), Scilex (SCLX), Ikena Oncology (IKNA), Barinthus Biotherapeutics (BRNS), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry. BioVie vs. Its Competitors Applied Therapeutics Repare Therapeutics CervoMed Assertio Sutro Biopharma Werewolf Therapeutics Scilex Ikena Oncology Barinthus Biotherapeutics MediciNova Applied Therapeutics (NASDAQ:APLT) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation. Does the media prefer APLT or BIVI? In the previous week, Applied Therapeutics had 3 more articles in the media than BioVie. MarketBeat recorded 4 mentions for Applied Therapeutics and 1 mentions for BioVie. Applied Therapeutics' average media sentiment score of 0.27 beat BioVie's score of 0.00 indicating that Applied Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Applied Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioVie 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend APLT or BIVI? Applied Therapeutics currently has a consensus target price of $6.10, indicating a potential upside of 1,284.16%. Given Applied Therapeutics' higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than BioVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50BioVie 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Which has better earnings & valuation, APLT or BIVI? BioVie has lower revenue, but higher earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApplied Therapeutics$460K135.64-$105.62M-$0.43-1.02BioVieN/AN/A-$32.12M-$79.10-0.08 Do institutionals & insiders believe in APLT or BIVI? 98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by company insiders. Comparatively, 2.4% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is APLT or BIVI more profitable? BioVie's return on equity of -100.88% beat Applied Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Applied TherapeuticsN/A -184.67% -84.02% BioVie N/A -100.88%-78.49% Which has more volatility & risk, APLT or BIVI? Applied Therapeutics has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, BioVie has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. SummaryApplied Therapeutics beats BioVie on 8 of the 15 factors compared between the two stocks. Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIVI vs. The Competition Export to ExcelMetricBioVieMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.22M$2.50B$5.52B$9.37BDividend YieldN/A1.80%4.74%4.12%P/E Ratio-0.088.9728.8823.80Price / SalesN/A687.56440.8796.33Price / CashN/A155.1435.0756.59Price / Book0.244.838.255.54Net Income-$32.12M$31.62M$3.25B$259.97M7 Day Performance-19.39%-5.28%-3.75%-4.67%1 Month Performance-37.32%3.12%2.99%3.28%1 Year Performance67.50%-2.00%25.35%17.92% BioVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIVIBioVie0.1932 of 5 stars$6.03+0.3%N/A+67.5%$11.22MN/A-0.0810APLTApplied Therapeutics4.1726 of 5 stars$0.46-0.4%$6.10+1,226.1%-92.5%$65.39M$460K-1.0730News CoverageUpcoming EarningsGap UpRPTXRepare Therapeutics3.2685 of 5 stars$1.50-0.7%$4.50+200.0%-54.4%$64.77M$53.48M-0.50180Upcoming EarningsCRVOCervoMed2.6501 of 5 stars$8.43+13.8%$22.57+167.8%-16.9%$64.49M$9.74M-3.874Upcoming EarningsAnalyst ForecastGap DownASRTAssertio1.7065 of 5 stars$0.70+3.3%$2.75+295.7%-44.8%$64.46M$124.96M-2.1720News CoverageUpcoming EarningsSTROSutro Biopharma3.4538 of 5 stars$0.80+5.3%$6.11+664.3%-77.4%$64.19M$62.04M-0.27240News CoverageHOWLWerewolf Therapeutics3.8905 of 5 stars$1.40-0.7%$8.33+495.2%-45.0%$63.27M$1.88M-0.8440News CoverageSCLXScilex2.082 of 5 stars$8.60-2.9%$455.00+5,190.7%-73.4%$61.59M$56.59M-0.3080News CoverageGap DownIKNAIkena OncologyN/A$1.27flat$3.00+136.2%N/A$61.29M$9.16M-1.4870News CoverageInsider TradeStock SplitAnalyst RevisionHigh Trading VolumeBRNSBarinthus Biotherapeutics2.2593 of 5 stars$1.97+31.5%$6.25+217.3%-1.7%$60.41M$14.97M-1.20107Upcoming EarningsGap DownHigh Trading VolumeMNOVMediciNova2.6972 of 5 stars$1.26+2.4%$7.00+455.6%+10.9%$60.33M$1M-5.4810News CoverageUpcoming Earnings Related Companies and Tools Related Companies Applied Therapeutics Competitors Repare Therapeutics Competitors CervoMed Competitors Assertio Competitors Sutro Biopharma Competitors Werewolf Therapeutics Competitors Scilex Competitors Ikena Oncology Competitors Barinthus Biotherapeutics Competitors MediciNova Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIVI) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIVI Stock Alerts